Reinhart Partners LLC. Has $117.70 Million Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Reinhart Partners LLC. cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,205,940 shares of the medical equipment provider's stock after selling 160,933 shares during the quarter. Lantheus makes up approximately 4.3% of Reinhart Partners LLC.'s portfolio, making the stock its 3rd biggest position. Reinhart Partners LLC. owned 1.76% of Lantheus worth $117,700,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Kestra Investment Management LLC bought a new position in shares of Lantheus in the 4th quarter worth about $27,000. Summit Securities Group LLC bought a new stake in Lantheus in the fourth quarter valued at $37,000. Parkside Financial Bank & Trust increased its stake in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. 1620 Investment Advisors Inc. bought a new stake in Lantheus in the 4th quarter valued at about $125,000. Finally, Daiwa Securities Group Inc. bought a new stake in Lantheus in the 4th quarter valued at about $136,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director now owns 318,650 shares in the company, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 36,068 shares of company stock valued at $3,008,051 over the last three months. Corporate insiders own 1.50% of the company's stock.

Lantheus Stock Performance

LNTH traded down $2.80 during midday trading on Tuesday, reaching $80.42. 1,190,596 shares of the company were exchanged, compared to its average volume of 1,005,876. The company's fifty day moving average price is $89.64 and its 200 day moving average price is $91.61. The company has a market cap of $5.56 billion, a price-to-earnings ratio of 13.38 and a beta of 0.11. Lantheus Holdings, Inc. has a one year low of $73.11 and a one year high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm's revenue for the quarter was up .8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.69 earnings per share. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Truist Financial decreased their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, B. Riley decreased their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.